| Concurrent high PD-L1 expression and CD8+ immune cell infiltration predict PD-1 blockade efficacy in advanced EGFR-mutant NSCLC patients Y Shimoda, R Shibaki, T Yoshida, S Murakami, M Shirasawa, ... Clinical Lung Cancer 23 (6), 477-486, 2022 | 11 | 2022 |
| Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis M Torasawa, T Yoshida, S Yagishita, Y Shimoda, M Shirasawa, ... Lung Cancer 167, 49-57, 2022 | 10 | 2022 |
| Anaphylaxis to three humanized antibodies for severe asthma: a case study K Jingo, N Harada, T Nishioki, M Torasawa, T Yamada, T Asao, H Takagi, ... Allergy, Asthma & Clinical Immunology 16, 1-6, 2020 | 9 | 2020 |
| Safety implications of switching pembrolizumab dosage from 200 mg every 3 weeks to 400 mg every 6 weeks in patients with advanced NSCLC RI Higashiyama, T Yoshida, S Yagishita, M Ohuchi, N Sakiyama, ... Journal of Thoracic Oncology 17 (10), 1227-1232, 2022 | 8 | 2022 |
| Reconsidering the cutoff value for sensitive and refractory relapses in extensive-stage SCLC in the era of immunotherapy M Torasawa, H Horinouchi, S Nomura, S Igawa, M Asai, H Ishii, H Wakui, ... Journal of Thoracic Oncology 19 (2), 325-336, 2024 | 5 | 2024 |
| CT Guided Needle Biopsy of Peripheral Lesions–Lesion Characteristics That May Increase the Diagnostic Yield and Reduce the Complication Rate M Tajima, S Togo, R Ko, Y Koinuma, I Sumiyoshi, M Torasawa, N Kikuchi, ... Journal of Clinical Medicine 10 (9), 2031, 2021 | 3 | 2021 |
| Lymphangioleiomyomatosis as a potent lung cancer risk factor: Insights from a Japanese large cohort study M Torasawa, T Shukuya, K Uemura, T Hayashi, T Ueno, S Kohsaka, ... Respirology, 2024 | 1 | 2024 |
| Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR … Y Uehara, Y Takeyasu, T Yoshida, A Tateishi, M Torasawa, Y Hosomi, ... ESMO Real World Data and Digital Oncology 5, 100058, 2024 | | 2024 |
| Implications of EGFR expression in MAPK dependency and adaptive immunity status of EGFR-mutated lung adenocarcinoma. M Torasawa, T Yoshida, K Shiraishi, S Yagishita, Y Uehara, J Miyakoshi, ... Journal of Clinical Oncology 42 (16_suppl), 8028-8028, 2024 | | 2024 |
| Efficacy and Safety of First-line Immunotherapy Plus Chemotherapy in Treating Elderly Patients With Extensive-stage Small Cell Lung Cancer M Sonoda, Y Shinno, K Tamura, Y Yamaguchi, J Miyakoshi, A Tateishi, ... B109. DIVING INTO DISCOVERY: CURRENTS OF BASIC SCIENCE AND IMMUNOTHERAPIES …, 2024 | | 2024 |
| Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression J Miyakoshi, T Yoshida, J Kashima, M Shirasawa, M Torasawa, ... Lung Cancer 191, 107788, 2024 | | 2024 |
| Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report M Torasawa, T Yoshida, K Shiraishi, N Goto, T Ueno, H Ichikawa, ... JTO Clinical and Research Reports 5 (4), 100657, 2024 | | 2024 |
| Identification of telomere maintenance gene variations related to lung adenocarcinoma risk by genome‐wide association and whole genome sequencing analyses K Shiraishi, A Takahashi, Y Momozawa, Y Daigo, S Kaneko, T Kawaguchi, ... Cancer Communications 44 (2), 287-293, 2024 | | 2024 |
| A Response to the Letter to the Editor:“A Paradigm Shift in First-Line Treatment Can Have Many Implications for Second-Line Treatment” M Torasawa, H Horinouchi Journal of Thoracic Oncology 19 (2), 351-352, 2024 | | 2024 |
| 1366P Association between the adverse events and serum concentrations of lorlatinib in patients with advanced ALK-positive lung cancer Y Shimoda, T Yoshida, RA Makihara, M Torasawa, A Tateishi, ... Annals of Oncology 34, S784-S785, 2023 | | 2023 |
| Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non‐small cell lung cancer from proteomic profiling of … M Torasawa, H Horinouchi, S Yagishita, H Utsumi, K Okuda, D Takekoshi, ... Thoracic Cancer 14 (29), 2909-2923, 2023 | | 2023 |
| Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver … Y Shimoda, T Yoshida, J Miyakoshi, M Torasawa, A Tateishi, ... Cancer Immunology, Immunotherapy 72 (8), 2613-2621, 2023 | | 2023 |
| Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer patients M Torasawa, T Yoshida, Y Takeyasu, Y Shimoda, A Tateishi, ... Cancer Medicine 12 (11), 12388-12401, 2023 | | 2023 |
| Co‐occurring KEAP1 and TP53 mutations in lung squamous cell carcinoma induced primary resistance to thoracic radiotherapy: A case report R Nishimura, T Yoshida, M Torasawa, T Kashihara, Y Ohe Thoracic Cancer 14 (2), 206-209, 2023 | | 2023 |
